MBS-301

重组人源化双功能单克隆抗体MBS301

Report date: 2025/02/12 09:48:42

Base Information

Drug NameMBS-301

Drug Alias Name注射用重组人源化双功能单克隆抗体MBS301MBS-301

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized

Mechanisms of ActionAnti-HER2

TargetsReceptor protein-tyrosine kinase erbB-2

Therapy Area/IndicationsSolid tumoursStomach NeoplasmsBreast Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesBeijing Mabworks Biotech Co Ltd

China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesBeijing Mabworks Biotech Co Ltd

Inactive CompaniesN/A

Active IndicationsSolid tumoursStomach NeoplasmsBreast Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A